CU20200085A7 - Tratamiento y prevención de alergias a ácaros de polvo doméstico - Google Patents

Tratamiento y prevención de alergias a ácaros de polvo doméstico

Info

Publication number
CU20200085A7
CU20200085A7 CU2020000085A CU20200085A CU20200085A7 CU 20200085 A7 CU20200085 A7 CU 20200085A7 CU 2020000085 A CU2020000085 A CU 2020000085A CU 20200085 A CU20200085 A CU 20200085A CU 20200085 A7 CU20200085 A7 CU 20200085A7
Authority
CU
Cuba
Prior art keywords
sub
allergies
prevention
treatment
dust mites
Prior art date
Application number
CU2020000085A
Other languages
English (en)
Inventor
Kuan-Wei Chen
Mirela Curin
Rudolf Valenta
Susanne Vrtala
Original Assignee
Worg Pharmaceutical Hangzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Worg Pharmaceutical Hangzhou Co Ltd filed Critical Worg Pharmaceutical Hangzhou Co Ltd
Publication of CU20200085A7 publication Critical patent/CU20200085A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>La presente invención se refiere a una proteína de fusión que tiene la fórmula (I) : X<sub>1</sub>-Y-X<sub>2</sub> , en donde X<sub>1</sub> y X<sub>2 </sub>comprenden cada uno de cuatro a seis fragmentos de alérgeno o variantes de los mismos fusionados entre sí, en donde estos fragmentos de alérgeno se derivan de al menos dos alérgenos del género <em>Dermatophagoides</em>, y en donde Y es una proteína portadora.</p>
CU2020000085A 2018-05-18 2019-05-17 Tratamiento y prevención de alergias a ácaros de polvo doméstico CU20200085A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18173258.7A EP3569612A1 (en) 2018-05-18 2018-05-18 Treatment and prevention of house dust mite allergies
PCT/EP2019/062800 WO2019219907A1 (en) 2018-05-18 2019-05-17 Treatment and prevention of house dust mite allergies

Publications (1)

Publication Number Publication Date
CU20200085A7 true CU20200085A7 (es) 2021-08-06

Family

ID=62530077

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000085A CU20200085A7 (es) 2018-05-18 2019-05-17 Tratamiento y prevención de alergias a ácaros de polvo doméstico

Country Status (17)

Country Link
US (1) US11771760B2 (es)
EP (2) EP3569612A1 (es)
JP (1) JP7407176B2 (es)
KR (1) KR102923426B1 (es)
CN (1) CN112313245B (es)
AU (1) AU2019270472B2 (es)
BR (1) BR112020023466A2 (es)
CA (1) CA3100175A1 (es)
CU (1) CU20200085A7 (es)
IL (1) IL278831B1 (es)
MA (1) MA52622A (es)
MX (1) MX2020012098A (es)
SA (1) SA520420599B1 (es)
SG (1) SG11202011123QA (es)
TW (1) TWI848947B (es)
WO (1) WO2019219907A1 (es)
ZA (1) ZA202007022B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112225816A (zh) * 2020-09-30 2021-01-15 四川携光生物技术有限公司 一种新型的吸入性过敏原融合蛋白及其构建方法、应用
CN116063442A (zh) * 2022-09-28 2023-05-05 深圳市龙岗区耳鼻咽喉医院 Der p2的3个B细胞表位肽及其应用
JP2025537236A (ja) * 2022-11-07 2025-11-14 ウォルグ ファーマシューティカルズ（チョーチアン）カンパニー，リミテッド アレルギー治療用ワクチン
TWI850940B (zh) 2022-12-30 2024-08-01 臺中榮民總醫院 重組乳酸菌及其用於同時治療及/或預防塵蟎及蟑螂過敏症之用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CN1326564C (zh) 1997-04-01 2007-07-18 科里克萨有限公司 单磷酰基脂质a的水性免疫佐剂组合物
US7439233B1 (en) * 1999-02-25 2008-10-21 Tai June Yoo Vaccine for house dust mite allergen using naked DNA
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
EP1908776A1 (en) * 2006-10-06 2008-04-09 Stallergenes Sa Mite fusion proteins
CA2718994C (en) * 2008-03-25 2017-06-13 Bial Industrial Farmaceutica, S.A. Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies
EP2295076A1 (en) 2009-09-10 2011-03-16 Biomay Ag Hypoallergenic hybrid polypeptides for the treatment of allergy
RU2630652C2 (ru) * 2011-06-09 2017-09-11 Биомей Аг Гибридные белки-носители пептидов в качестве вакцин от аллергии
WO2014045084A1 (es) * 2012-09-20 2014-03-27 Universidad De Cartagena Proteínas de fusión con representación de diferentes alergenos: propuesta de vacuna para alergia a los ácaros
WO2015070925A1 (en) * 2013-11-15 2015-05-21 Biomay Ag Fusion proteins
GB201602850D0 (en) * 2016-02-18 2016-04-06 Bial Ind Farmaceutica S A Fusion proteins

Also Published As

Publication number Publication date
ZA202007022B (en) 2023-05-31
BR112020023466A2 (pt) 2021-03-30
MX2020012098A (es) 2021-03-09
SA520420599B1 (ar) 2024-06-23
IL278831A (en) 2021-01-31
TW202010751A (zh) 2020-03-16
CN112313245B (zh) 2025-03-07
JP2021524280A (ja) 2021-09-13
AU2019270472B2 (en) 2024-09-19
KR20210010931A (ko) 2021-01-28
CN112313245A (zh) 2021-02-02
TWI848947B (zh) 2024-07-21
IL278831B1 (en) 2026-01-01
EP3569612A1 (en) 2019-11-20
JP7407176B2 (ja) 2023-12-28
US20210128718A1 (en) 2021-05-06
US11771760B2 (en) 2023-10-03
WO2019219907A1 (en) 2019-11-21
AU2019270472A1 (en) 2020-11-26
MA52622A (fr) 2021-03-24
EP3794020A1 (en) 2021-03-24
KR102923426B1 (ko) 2026-02-05
SG11202011123QA (en) 2020-12-30
CA3100175A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
CU20200085A7 (es) Tratamiento y prevención de alergias a ácaros de polvo doméstico
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
WO2016007576A3 (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
EA201590384A1 (ru) 6-аминокислота-гетероарилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
MX2020006460A (es) Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
BR112017002970A2 (pt) novas piridazonas e triazinonas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
BR112015027381A8 (pt) pirimidinas substituídas por heterocicloalquila ligadas ao c e seus usos
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA202091521A1 (ru) ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
EP2982691A4 (en) MONOCLONAL WIDE SPECTRUM ANTIBODY FOR IDENTIFYING THE STRUCTURAL HA1 DOMAIN OF INFLUENZA AVIRUS HEMAGGLUTININE PROTEINS
CO6400223A2 (es) Derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil)benzotiazoles y bencimidazoles : preparación, aplicación como medicamentos y utilización como inhibidores de met
CA3010327A1 (en) Aryl substituted pyrimidines for use in influenza virus infection
EA202190810A1 (ru) Способы и наборы для получения цельной крови с инактивированным патогеном
MX2019013815A (es) Inhibidor de antigenos de superficie del virus de la hepatitis b.
EA201600304A1 (ru) Применение замещенных дигидрооксиндолилсульфонамидов или их солей для повышения толерантности растений к стрессу
CY1123976T1 (el) Νεες ενωσεις με τριπλη θρομβολυτικη, αντιθρομβωτικη δραση και δραση δεσμευσης ελευθερων ριζων και συνθεση, νανομετρικη δομη και χρηση αυτων
MX2017016030A (es) Derivado de dihidropirrolopirazol sustituido.
EA201692028A1 (ru) Применение замещенных оксотетрагидрохинолинилсульфонамидов или их солей для повышения стрессоустойчивости растений
MX2023013335A (es) Anticuerpos anti-tigit y usos de los mismos.
MX376450B (es) Soporte de hilo dental.
BR112015028871A2 (pt) novos compostos de 3,4-dihidro-2h-isoquinolina-1-ona e 2,3-dihidro-isoindol-1-ona
MX420767B (es) Proteina de union al factor h modificada
EP4216995A4 (en) ATTENUATED ISOLATE OF INFECTIOUS BRONCHITIS VIRUS STRAIN DMV1639
ATE328905T1 (de) Igg3 immunogloblin als schutzsmarker gegen viren infektiösen krankheiten und seine verwendungen
MX2021006696A (es) Derivado de cicloalcano-1,3-diamina.